[1]Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metforminbased combination therapy for type 2 diabetes: a systematic review and metaanalysis\[J\]. Ann Intern Med, 2016, 164(11): 740-751.
[2]Podhorecka M, Ibanez B, Dmoszynska A. Metforminits potential anticancer and antiaging effects\[J\]. Postepy Hig Med Dosw (Online), 2017, 70(3): 170-175.
[3]Rattan R, Graham RP, Maguire JL, et al. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo\[J\]. Neoplasia, 2011, 13(5): 483-491.
[4]Lan F, Nottke AC, Shi Y. Mechanisms involved in the regulation of histone lysine demethylases\[J\]. Curr Opin Cell Biol, 2008, 20(3): 316-325.
[5]Konovalov S, GarciaBassets I. Analysis of the levels of lysinespecific demethylase 1(LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines\[J\]. J Ovarian Res, 2013, 6(1): 75.
[6]Lv T, Yuan D, Miao X, et al. Overexpression of LSD1 promotes proliferation, migration and invasion in nonsmall cell lung cancer\[J\]. PLoS One, 2012, 7(4): e35065.
[7]Lim S, Janzer A, Becker A, et al. Lysinespecific demethylase 1 (LSD1) is highly expressed in ERnegative breast cancers and a biomarker predicting aggressive biology\[J\]. Carcinogenesis, 2010, 31(3): 512-520.
[8]Zhang J, Zhao D, Li Q, et al. Upregulation of LSD1 promotes migration and invasion in gastric cancer through facilitating EMT\[J\]. Cancer Manag Res, 2019, 21: 4481-4491.
[9]Chen C, Ge J, Lu Q, et al. Expression of Lysinespecific demethylase 1 in human epithelial ovarian cancer\[J\]. J Ovarian Res, 2015, 8: 28.
[10]Fu X, Zhang P, Yu B, et al. Advances toward LSD1 inhibitors for cancer therapy\[J\]. Future Med Chem, 2017, 9(11): 1227-1242.
[11]Wei Y, Han T, Wang R, et al. LSD1 negatively regulates autophagy through the mTOR signaling pathway in ovarian cancer cells\[J\]. Oncol Rep, 2018, 40(1): 425-433.
[12]Coburn SB, Bray F, Sherman ME, et al. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype\[J\]. Int J Cancer, 2017, 140(11): 2451-2460.
[13]Lengyel E, Litchfield LM, Mitra AK, et al. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models\[J\]. Am J Obstet Gynecol, 2015, 212(4): 479.e1-479.e10.
[14]Rattan R, Giri S, Hartmann LC, et al. Metformin attenuates ovarian cancer cell growth in an AMpkinase dispensable manner\[J\]. J Cell Mol Med, 2019, 15(1): 166-178.
[15]Liu Y, Zhang Y, Jia K, et al. Metformin inhibits the proliferation of A431 cells by modulating the PI3K/Akt signaling pathway\[J\]. Exp Ther Med, 2015, 9(4): 1401-1406.
[16]Shao G, Wang J, Li Y, et al. Lysinespecific demethylase 1 mediates epidermal growth factor signaling to promote cell migration in ovarian cancer cells\[J\]. Sci Rep, 2015, 5: 15344.
[17]Li Y, Wan X, Wei Y, et al. LSD1mediated epigenetic modification contributes to ovarian cancer cell migration and invasion\[J\]. Oncol Rep, 2016, 35(6): 3586-3592.
|